Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | PTAFR | P25105 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.76 |
| ▸ | PRKCG | P05129 | 1/20 | 0.76 |
| ▸ | PRKCB | P05771 | 1/20 | 0.76 |
| ▸ | PRKCA | P17252 | 1/20 | 0.76 |
| ▸ | PRKCH | P24723 | 1/20 | 0.76 |
| ▸ | AKT1 | P31749 | 1/20 | 0.76 |
| ▸ | PRKCI | P41743 | 1/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.76 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.76 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30655807 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL433361 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30652762 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30652521 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL34464893 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL435191 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL2534238 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30366852 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30650457 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL1392735 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-11479802-B2 | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-7906147-B2 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100119612-A1 | NANOPARTICLES COMPRISING NON-CRYSTALLINE DRUG | BEND RESEARCH, INC | 2010-05-13 | — | — | US | disclosed |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | ADRA1D 4283/4885PTAFR 3766/4885HTR1D 1631/4885 |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | TFRC, FABP1, SCARB1 | ADRA1D 2800/4885PTAFR 748/4885HTR1D 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.